



## **Axonics® to Present at the Barclays Global Healthcare Conference**

February 25, 2020

IRVINE, Calif.--(BUSINESS WIRE)--Feb. 25, 2020-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the Barclays Global Healthcare Conference, Tuesday, March 10 at 3:50pm ET in Miami Beach, FL, and will be available for meetings with institutional investors.

To access the live webcast of the fireside chat, please visit the Events & Presentations page of the Investor Relations section of the Company's website at [ir.axonics.com](http://ir.axonics.com). A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days.

### **About Axonics Modulation Technologies, Inc.**

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company's website at [www.axonics.com](http://www.axonics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200225005163/en/): <https://www.businesswire.com/news/home/20200225005163/en/>

### **Axonics' Contact**

Axonics Modulation Technologies, Inc.  
Dan Dearen, +1-949-396-6320  
President & Chief Financial Officer  
[ir@axonics.com](mailto:ir@axonics.com)

### **Investor & Media Contact**

W2Opure  
Matt Clawson, +1-949-370-8500  
[mclawson@w2ogroup.com](mailto:mclawson@w2ogroup.com)

Source: Axonics Modulation Technologies, Inc.

### **Axonics' Contact**

Axonics Modulation Technologies, Inc.  
Dan Dearen, +1-949-396-6320  
President & Chief Financial Officer  
[ir@axonics.com](mailto:ir@axonics.com)

### **Investor & Media Contact**

W2Opure  
Matt Clawson, +1-949-370-8500  
[mclawson@w2ogroup.com](mailto:mclawson@w2ogroup.com)